ArticleBlood advances2024
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.
Sheng F Cai et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
18 papers cite it
this papercites it